...
首页> 外文期刊>Retina >Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis.
【24h】

Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis.

机译:用于眼内药物递送的新型脂质前药的评估:阿昔洛韦二磷酸二羟甲基甘油在患有单纯疱疹病毒1型视网膜炎的兔子模型中的作用。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Acyclovir diphosphate dimyristoylglycerol is a lipid prodrug of acyclovir that forms liposomes and provides substantial activity against herpes simplex virus, acyclovir-resistant strains of herpes simplex virus, and human cytomegalovirus. We therefore tested this promising new drug in a rabbit model of herpes simplex retinitis. METHODS: A total of 22 pigmented rabbits were pretreated with either acyclovir diphosphate dimyristoylglycerol, ganciclovir, acyclovir, or buffer. Retinae then were inoculated with herpes simplex virus-1 or buffer 1 week after the injection of drug. In another experiment we compared the effects of acyclovir diphosphate dimyristoylglycerol and acyclovir diphosphate dioleoylglycerol on the optical clarity of vitreous. RESULTS: Animals injected intravitreally with acyclovir diphosphate dimyristoylglycerol showed retinitis that was less severe than that in animals injected with ganciclovir, acyclovir, and buffer; differences in grading scores of the retinitis between animals injected with acyclovir diphosphate dimyristoylglycerol and those injected with buffer were statistically significant (P = 0.0015). Vitreous and optical media became clear 4 days after acyclovir diphosphate dioleoylglycerol injection compared with 10 days after with acyclovir diphosphate dimyristoylglycerol injections. CONCLUSION: Acyclovir diphosphate dimyristoylglycerol had prolonged antiviral activity against herpes simplex virus-1 retinitis in a rabbit model. This drug delivery system, modified to improve optical clarity, may allow long-acting intravitreal treatment of cytomegalovirus retinitis and other retinal diseases.
机译:背景:阿昔洛韦二磷酸二甲基丙二酰甘油是阿昔洛韦的脂质前药,可形成脂质体,对单纯疱疹病毒,单纯疱疹病毒无阿昔洛韦耐药株和人巨细胞病毒具有实质性活性。因此,我们在单纯疱疹性视网膜炎的兔子模型中测试了这种有前途的新药。方法:总共22只有色素的兔子用阿昔洛韦二磷酸二羟丙基甘油,更昔洛韦,阿昔洛韦或缓冲液预处理。然后在注射药物1周后用单纯疱疹病毒1或缓冲液接种视网膜。在另一个实验中,我们比较了阿昔洛韦二磷酸二羟甲基甘油基甘油和阿昔洛韦二磷酸二油酰基甘油对玻璃体光学透明度的影响。结果:玻璃体腔注射阿昔洛韦二磷酸二豆蔻酰甘油的动物的视网膜炎不及更昔洛韦,阿昔洛韦和缓冲液所致。注射阿昔洛韦二磷酸二羟甲基甘油的动物与注射缓冲液的动物之间的视网膜炎分级评分差异具有统计学意义(P = 0.0015)。注射阿昔洛韦二磷酸二羟甘油甘油酯后第4天玻璃体和光学介质变得清晰,而注射阿昔洛韦二磷酸二甲基丙二醇甘油酯后10天。结论:阿昔洛韦二磷酸二豆蔻酰甘油在兔模型中具有延长的抗单纯疱疹病毒1型视网膜炎的抗病毒活性。经过改进以改善光学清晰度的这种药物输送系统,可以长效玻璃体内治疗巨细胞病毒性视网膜炎和其他视网膜疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号